Full Text View
Tabular View
No Study Results Posted
Related Studies
Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma
This study has been terminated.
Study NCT01445340   Information provided by National Institutes of Health Clinical Center (CC)

First Received on September 30, 2011.   Last Updated on May 3, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Mycosis Fungoides
Cutaneous T-Cell Lymphoma
Neoplasms
Additional conditions recognized in this trial
Lymphoma
Lymphoma, T-Cell
Lymphoma, T-Cell, Cutaneous
Mycoses
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Interventions listed in this trial
Romidepsin (FR901228)
Additional drug interventions recognized in this trial
Romidepsin
More general drug interventions related to this trial
Antibiotics, Antineoplastic
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services